Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis B Cortot

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
BMC Cancer|February 14, 2018
Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot studyCecile Olivier, Jean-Marie Grosbois, Alexis B Cortot, et al.
Preventive Medicine Reports|June 6, 2018
Beliefs and behavior regarding e-cigarettes in a large cross-sectional surveySébastien Couraud, Alexis B Cortot, Xavier B Pivot, et al.
Lung Cancer (Amsterdam, Netherlands)|October 31, 2016
High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble formMarie-Christine Copin, Marie Lesaffre, Mélanie Berbon, et al.
European Radiology|February 18, 2017
Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancerGrégory Kuchcinski, Emilie Le Rhun, Alexis B Cortot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 10, 2018
Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC PatientsClotilde Descarpentries, Frédéric Leprêtre, Fabienne Escande, et al.
Cancer Research|November 23, 2012
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathwayAlexis B Cortot, Claire E Repellin, Takeshi Shimamura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2020
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping MutationsPhilippe Jamme, Marie Fernandes, Marie-Christine Copin, et al.
FEBS Letters|July 19, 2023
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding siteMarie Fernandes, Sonia Paget, Zoulika Kherrouche, et al.
Clinical Lung Cancer|October 31, 2013
Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomasAlexis B Cortot, Mohamad Younes, Ghislaine Martel-Planche, et al.
Clinical Lung Cancer|June 1, 2019
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine PracticePhilippe Jamme, Clotilde Descarpentries, Radj Gervais, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
BMC Cancer|February 14, 2018
Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot studyCecile Olivier, Jean-Marie Grosbois, Alexis B Cortot, et al.
Preventive Medicine Reports|June 6, 2018
Beliefs and behavior regarding e-cigarettes in a large cross-sectional surveySébastien Couraud, Alexis B Cortot, Xavier B Pivot, et al.
Lung Cancer (Amsterdam, Netherlands)|October 31, 2016
High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble formMarie-Christine Copin, Marie Lesaffre, Mélanie Berbon, et al.
European Radiology|February 18, 2017
Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancerGrégory Kuchcinski, Emilie Le Rhun, Alexis B Cortot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 10, 2018
Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC PatientsClotilde Descarpentries, Frédéric Leprêtre, Fabienne Escande, et al.
Cancer Research|November 23, 2012
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathwayAlexis B Cortot, Claire E Repellin, Takeshi Shimamura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2020
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping MutationsPhilippe Jamme, Marie Fernandes, Marie-Christine Copin, et al.
FEBS Letters|July 19, 2023
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding siteMarie Fernandes, Sonia Paget, Zoulika Kherrouche, et al.
Clinical Lung Cancer|October 31, 2013
Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomasAlexis B Cortot, Mohamad Younes, Ghislaine Martel-Planche, et al.
Clinical Lung Cancer|June 1, 2019
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine PracticePhilippe Jamme, Clotilde Descarpentries, Radj Gervais, et al.
Pageof 8